Smith & Nephew PLC
SNN
Company Profile
Business description
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Contact
Hatters Lane
Building 5, Croxley Park
WatfordHertfordshireWD18 8YE
GBRT: +44 1923477100
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2025
Employees
17,349
Stocks News & Analysis
stocks
Ask the analyst: How reliant are Guzman shares on international growth?
A year on from Guzman’s IPO, I catch up with Johannes Faul to explore what is baked into GYG’s valuation.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,006.80 | 116.00 | 1.30% |
| CAC 40 | 7,822.67 | 0.67 | 0.01% |
| DAX 40 | 24,289.51 | 81.42 | -0.33% |
| Dow JONES (US) | 44,277.83 | 206.66 | -0.46% |
| FTSE 100 | 8,992.12 | 19.48 | 0.22% |
| HKSE | 24,825.66 | 326.71 | 1.33% |
| NASDAQ | 20,891.20 | 5.55 | 0.03% |
| Nikkei 225 | 39,819.11 | 82.08 | -0.21% |
| NZX 50 Index | 12,880.40 | 25.01 | -0.19% |
| S&P 500 | 6,293.84 | 3.52 | -0.06% |
| S&P/ASX 200 | 8,757.20 | 118.20 | 1.37% |
| SSE Composite Index | 3,534.48 | 17.66 | 0.50% |